# Membrane Lipid Replacement in Fibromyalgia

> **NCT03288389** · NA · SUSPENDED · sponsor: **Institute for Molecular Medicine** · enrollment: 60 (estimated)

## Conditions studied

- Fibromyalgia

## Interventions

- **DIETARY_SUPPLEMENT:** NTFactor Lipids®
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT03288389
- **Lead sponsor:** Institute for Molecular Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2017-05-01
- **Primary completion:** 2022-05-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** until further notice due to COVID-19 pandemic.
- **Last updated:** 2020-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03288389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03288389, "Membrane Lipid Replacement in Fibromyalgia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03288389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*